Pmgc Holdings Inc.

ELAB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001840563

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $12.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data not computable: short runway, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Mar 30, 2026 221 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.96 2026-11-04; market equity $1.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

portfolio of four (4) wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors: Inc. ("Northstrive Biosciences") is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. Capital") is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 58.6						
Gross profitability	1.4%	32.3%		90.4	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(16.6%)	(6.6%)		26.7	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 2						
Solvency, sleeve percentile 75.6						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	not computable	(0.37)				
one or more required annual facts are missing						
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	1.74x	2.94x		75.6	828	2025-12-31
Growth and financing, sleeve percentile 99.4						
Revenue growth, three-year compound	not computable	10.0%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 3						
Net share issuance, one year	13,669.6%	2.5%		99.4	630	2026-03-30

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 13669.6%
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-04 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(99.8%)	(2.1%)	0
Distance from 52-week high	(99.9%)	(30.4%)	0
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(477.3%)	(1.0%)	2
Book value to price	12.53	0.29	99
Sales to price	0.44	0.30	62
Composite equity issuance, five years	not computable	21.4%	
Relative strength against the sector, log excess return	(6.16)	(0.19)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	84 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$126,716

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$185,314	2025-12-31	2026-03-30	10-K	26-035937
2	assets	us-gaap:Assets	$12.9M	2025-12-31	2026-03-30	10-K	26-035937
3	net income	us-gaap:NetIncomeLoss	-$7.7M	2025-12-31	2026-03-30	10-K	26-035937
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.9M	2025-12-31	2026-03-30	10-K	26-035937
5	assets	us-gaap:Assets	$9.0M	2024-12-31	2026-03-30	10-K	26-035937
6	current assets	us-gaap:AssetsCurrent	$6.9M	2025-12-31	2026-03-30	10-K	26-035937
7	current liabilities	us-gaap:LiabilitiesCurrent	$3.9M	2025-12-31	2026-03-30	10-K	26-035937
8	revenue	us-gaap:Revenues	$590,084	2025-12-31	2026-03-30	10-K	26-035937
9	revenue	us-gaap:Revenues	$1.7M	2023-12-31	2024-03-29	10-K	24-027576
10	assets	us-gaap:Assets	$5.2M	2023-12-31	2025-03-28	10-K	25-003553
11	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,159,112	2026-03-30	2026-03-30	10-K	26-035937
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	707,106	2025-03-26	2025-03-28	10-K	25-003553

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.